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Research Paper
Reduced thermal sensitivity and increased
opioidergic tone in the TASTPM mouse model of
Alzheimer’s disease
Yahyah Aman, Thomas Pitcher, Raffaele Simeoli, Clive Ballard, Marzia Malcangio*
Abstract
Individuals with Alzheimer’s disease (AD) are in susceptible patient groups in which pain is an important clinical issue that is often
underdiagnosed.However, it is unclearwhether decreasedpain complaints in patientswithAD result fromelevatedpain tolerance or an
impaired ability to communicate sensations.Here,weexplored if AD-relatedpathology is present in key regionsof thepainpathway and
assessed whether nociceptive thresholds to acute noxious stimulation are altered in the double-mutant APPswe 3 PS1.M146V
(TASTPM) transgenic mousemodel of AD. TASTPMmice exhibited an age-dependant cognitive deficit at the age of 6 months, but not
at 4 months, a deficit that was accompanied by amyloid plaques in the cortex, hippocampus, and thalamus. In the spinal cord,
b-amyloid (APP/Ab) immunoreactivity was observed in dorsal and ventral horn neurons, and the expression of vesicular glutamate
transporter 2 (VGLUT2)was significantly reduced,while the expression of the inhibitory peptides enkephalinswas increased in TASTPM
dorsal horn, consistent with an increased inhibitory tone. TASTPMmice displayed reduced sensitivity to acute noxious heat, whichwas
reversed by naloxone, an opioid antagonist. This study suggests that increased inhibition and decreased excitation in the spinal cord
may be responsible for the reduced thermal sensitivity associated with AD-related pathology.
Keywords: Alzheimer’s disease, Nociceptive threshold, Transgenic mice, Opioids
1. Introduction
Alzheimer’s disease (AD) is a progressive and irreversible age-
related neurodegenerative disease. It is themost common form of
dementia (.60%) in the elderly population, affecting around 35
million people worldwide and ;800,000 people in the United
Kingdom.25,31,43 The prevalence of AD is approximately 5% in
people older than 65 years, increasing to approximately 30% by
the age of 85 years.22 The aetiology of the disease is complex due
to the heterogeneity of the disorder. Alzheimer’s disease is
clinically characterised by a global deficit in cognition ranging
from loss of memory to impaired judgement and reasoning.43
Neuropathological hallmarks of AD are extracellular b-amyloid
(Ab) plaques and intracellular neurofibrillary tangles composed of
abnormally hyperphosphorylated microtubule-associated pro-
tein tau. These hallmarks are accompanied by neuronal loss,
synaptic dysfunction, brain atrophy, and inflammation.40
Accumulating evidence indicates that a significant alteration in
pain perception is an important clinical issue in patients with AD.
Assessment and treatment of pain in AD are often difficult, thereby
having a negative impact on the quality of life.1,8 In fact, prevalence
of pain in dementia has been estimated to be ;50-80%, and the
presence of pain is associated with distress and neuropsychiatric
symptoms.17,8 Recent studies suggest that patients with AD do not
report pain as often and are prescribed analgesics less frequently
comparedwith age-matched individualswithout AD.36,7 In addition,
patients with AD manifest increased tolerance to ischemic pain but
no change in the sensory discriminative aspect of pain compared
with healthy controls, thereby suggesting an alteration in the
emotional dimension of pain.2 Moreover, histological evidence
shows AD-related cytoskeletal pathology and Ab deposition in the
intralaminar nuclei of the thalamus and neurofibrillary tangle in the
spinal cord.38,34 Both the spinal cord and the thalamus are key
regions in the pain pathway which are involved in processing and
relaying nociceptive inputs to supraspinal structures. In patientswith
dementia, the sensory–discriminative aspect of pain, which is
referred to as the lateral nociceptive pathway, may be preserved.12
However, in AD the cognitive–evaluative and emotional–affective
dimensionsof pain, representedby themedial nociceptivepathway,
may be affected due to neurodegeneration within the limbic
structures, hippocampus, and prefrontal cortex.18 Collectively,
evidence suggesting elevation in pain tolerance exhibited by
patients with AD has made it difficult to understand whether
decreased pain complaints are related to altered pain processing or
the deteriorating ability of these patients to communicate which
hinders their capacity to report pain.37 Therefore, a better un-
derstanding of the pathophysiological mechanisms underlying
alterations in sensory transmission is essential for improving the
clinical management of pain in patients with AD. In this study, we
assessednociceptive behaviour andexploredAD-relatedpathology
in the spinal cord of a double-mutant transgenic TASTPM mouse
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model of AD that carries mutant versions of the APP (APPswe) and
presenilin-1 (PS1.M146V) associated with familial forms of AD.16
2. Methods
2.1. Animals
Experiments were performed on 4- to 7-month-old adult male and
female heterozygous double-mutant TASTPM transgenic mice.
These mice were generated using TAS10 transgenic mice express-
ing the Swedish mutant human amyloid precursor protein (APP)
(695-aa isoform) under the control of themurine Thy-1promoter and
transgenicmice overexpressing presenilin-1M146Vmutation (TPM)
driven through the murine Thy-1 promoter.32,16 Briefly, TAS10 (Thy-
1.APPswe) mice were generated and backcrossed onto a pure
C57BL/6 background before being crossed with TPM (Thy-1.
PSEN-1.M146V) mice to produce heterozygous double-mutant
TASTPM mice (GlaxoSmithKline). Age- and gender-matched
C57BL/6J obtained from Charles River Laboratories were used as
controls. All animals were housed in the Biological Services Unit,
King’s College London; maintained in 12 hours day/night cycle with
access to food and water ad libitum; and were allowed acclimatisa-
tion for 7 days before behavioural experiments. All experimentswere
performed in accordance with United Kingdom Home Office
Regulations (Animal Scientific Procedures Act, 1986).
2.2. Novel object recognition test
Animals were placed in the neutral test arena, circular open maze
(603 50 cm) obtained from Ugo Basile (Varese, Italy), and allowed
to freely explore it 3 times (10minutes each) to habituate to both the
arena and experimenter before the beginning of the experiment.
After each exploration, animals were removed from the arena,
which was then cleaned with 70% ethanol. After the habituation
period, 2 identical objects (23black cube, F) were placed inside the
arena, at equal distance from the walls. Mice were placed in the
arena at the furthest distance from the objects and allowed to freely
explore the objects for 10 minutes. Subsequently, following
a retention period of 24 hours, mice were placed back into the
arena with one of the familiar objects (F) replaced by one novel
object (white sphere,N) in the same locationwithNbeing different in
colour, shape, and texture. The mice were then allowed to freely
explore both objects for 10minutes. Theobjects and thearenawere
thoroughly cleanedwith 70%ethanol between each animal to avoid
any odour recognition. The mouse was considered to be exploring
the object when its headwas facing the object at a distance of 2 cm
or less. Mice were individually observed and the time taken to
explore each objectwas recorded to the nearest 0.01 seconds. The
time difference in exploring each object was calculated:
Difference ¼ N2 F
2.3. Locomotor function (Roto-Rod)
Locomotor function was assessed using an accelerating Roto-Rod
(Series 8, IITC, LosAngeles, CA)with rubber drums set to accelerate
from 4 to 40 rpm over a period of 300 seconds. Any mice remaining
on the apparatus after 300 seconds were removed and their time
was recordedas300seconds. Three separate trialswereperformed
for each animal, separated by at least 15 minutes.
2.4. Mechanical thresholds: von Frey filaments
Static mechanical withdrawal thresholds were assessed by
applying calibrated von Frey monofilaments (0.007-1.00g) to
the plantar surface of the hind paw. The 50% paw withdrawal
threshold (PWT) was determined by increasing or decreasing
stimulus intensity and estimated using the Dixon “up–down”
method.6 Unrestrained mice were placed individually and
acclimatised up to 60 minutes, prior testing, in acrylic cubicles
(8 3 5 3 10 cm) on a wire mesh grid, providing access to the
underside of the hind paw. Monofilaments were applied
perpendicular to the plantar surface of the selected hind paw
and then held in this position with enough force to cause a slight
bend in the filament for approximately 3 seconds or until an
abrupt withdrawal of the hind paw from the stimulus, the latter
defining a positive response. Each test started with the
application of 0.07g filament and each hind paw was assessed
alternately with approximately 30-second gap between each
application. Stimulus intensity was increased in a sequence until
a positive response was achieved or the maximum strength
stimulus of 1.00g filament failed to induce a positive response, to
avoid tissue damage. If the mouse withdrew its hind paw on
application of a filament, the next lower force filament in the
sequence was applied and vice versa until there was a change in
response from the mouse. Following a positive response, 4
successive filaments were assessed according to the “up–down”
sequence, with no filament applied more than 3 times, to prevent
sensitization. A 50% PWT (g) was determined using the
“up–down” procedure.11
2.5. Thermal thresholds: hot-plate test
Response to noxious heat stimulation of the paws and tail was
assessed using the hot plate. Mice were placed on the hot-plate
device set at temperature ;52.5˚C (60.2˚C). The latency to
respond (licking of hind paw or flicking of hind paw or jumping)
was recorded to the nearest 0.01 seconds to obtain the
withdrawal response latency. A cutoff time of 45 seconds was
used at which point the animals were removed to avoid tissue
injury.
2.6. Thermal thresholds: Hargreaves test
Thermal nociceptive thresholds of the hind paw were determined
by the Hargreaves method using the plantar test (37370; Ugo
Basile).14 Unrestrained mice were acclimatised in acrylic cubicle
(8 3 5 3 10 cm) on a uniform glass surface up to 60 minutes
before testing. An infrared light source was directed onto the
plantar surface of the hind paw, and the paw withdrawal latency
was automatically measured in seconds. Three responses for
each hind paw were recorded on each testing occasion with at
least 1-minute between stimuli. To avoid tissue injury, the
maximum stimulus latency period permitted was 20 seconds.
2.7. Carrageenan model of inflammatory pain
Carrageenan obtained from Sigma-Aldrich (Gillingham, United
Kingdom) was dissolved in sterile saline (0.9% NaCl) at 1% and
injected onto the intraplantar surface of the right hind paw of 6- to
7-month-old TASTPM mice and age- and gender-matched
C57BL/6J (controls). Mechanical (von Frey filaments) and thermal
(Hargreaves test) nociceptive thresholdswere recordedbefore and
at intervals of 3 hours and 24 hours after carrageenan injection.
2.8. Naloxone administration
Naloxone hydrochloride (1 mg/kg) was obtained from Sigma-
Aldrich and dissolved in sterile saline. Either naloxone or saline
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(vehicle) was administrated intraperitoneally in TASTPM and wild-
type (WT) controls. Baseline paw withdrawal latencies were
recorded before naloxone administration, and on the day of
testing the effect of the drug administrated was monitored over
a period of 3 hours, with hot-plate tests performed at 30 minutes,
90 minutes, and 180 minutes after administration.
2.9. Immunohistochemistry
Naive WT (6-7 months old) and TASTPM (6-7 months and 12
months old) mice were terminally anaesthetised with an
overdose of sodium pentobarbital (;150 mg/kg body weight,
Euthatal, Merial Animal Health, Woking, United Kingdom) and
perfused transcardially with heparinised (1 U/mL) sterile saline
(0.9%NaCl) followed by 4% paraformaldehyde fixative solution
containing 1.5% picric acid in phosphate buffer (PB, 0.1M, pH
7.4). Spinal cords (L3-L6) and brains were removed and
immersion-fixed in 4% paraformaldehyde fixative solution
containing 1.5% picric acid for 24 hours at 4˚C. Subsequently,
spinal cords and brains were cryoprotected in a solution of
20% sucrose in PB at 4˚C for at least 48 hours and
subsequently embedded in optimum cutting temperature
(OCT, BDH, Leicestershire, United Kingdom) medium and
then snap-frozen using liquid nitrogen and stored at 280˚C.
Transverse spinal cord and coronal brain sections were cut
(20 mm thick) using a cryostat and thaw mounted onto
Superfrost Plus microscope slides (BDH). Free-floating spinal
cord sections were cut at 30-mm thickness and transferred to
phosphate-buffered saline (PBS) in 24-well plates. Slide-
mounted sections were blocked with 1% (w/v) bovine serum
albumin (BSA, Sigma-Aldrich) and 0.2% (w/v) sodium azide
(Sigma-Aldrich) in 0.1% Triton X-100 (BDH) in PBS for 1 hour
and incubated overnight for single staining with rabbit anti–
met-enkephalin (ENK) and mouse anti–b-amyloid 1-16 (6E10)
or with a combination of primary antibodies. Double staining
was performed using rabbit anti–vesicular glutamate trans-
porter 1 (VGLUT1) with guinea pig anti–vesicular glutamate
transporter 2 (VGLUT2); and mouse anti-6E10 in combination
with the following primary antibodies: rabbit anti–glial fibrillary
acidic protein (GFAP), rabbit anti–ionized calcium binding
adaptor molecule 1 (IBA1), rabbit anti–neuronal nuclei (NeuN),
or sheep anti–calcitonin gene-related peptide (CGRP). Details
of the source and dilution of the primary antibodies are
provided in Table 1. Sections were then incubated for 2 hours
with the appropriate Alexa Fluor 488- or 546-conjugated
antibody (1:500; Molecular Probes, USA). Where spinal cord
sections were stained with 6E10, pretreatment with 70%
formic acid was performed. All antibody solutions were
prepared in PBS with 1% BSA, 0.1% Triton X-100, and 0.2%
sodium azide. Where spinal cord sections were stained with
VGLUT1 and VGLUT2, 10% BSA was used in antibody solution
instead of 1%. Free-floating spinal cord sectionswere blockedwith
1% BSA, 0.1% Triton X-100, and 0.2% sodium azide in PBS and
incubated for 72 hours on a shaker at 4˚C with the primary
antibodies (Table 1):mouse anti-6E10 and rabbit anti–neurokinin 1
receptor (NK1R). Sections were then incubated with the appropri-
ate Alexa Fluor 488- or 546-conjugated antibody (1:500;Molecular
Probes, USA) overnight on a shaker at 4˚C and thenmounted onto
microscope slides. All slides were coverslipped with the
Vectashield Mounting Medium containing nuclear marker 49,6-
diamidino-2-phenylindole·2HCl (DAPI; Vector Laboratories, Peter-
borough, United Kingdom), and fluorescent stainingwas visualized
using the Zeiss LSM710 confocal microscope (Zeiss, Cambridge,
United Kingdom).
2.10. Quantitative assessment of fluorescence intensity
Quantitative assessment of VGLUT1, VGLUT2, and met-ENK
immunoreactivity was calculated by determining immunoflu-
orescence intensity within 1 3 104 mm2 boxes placed onto
areas of the lateral, central, and medial dorsal horn laminae I-
III and laminae IV-VI (VGLUT1 and VGLUT2 only) using
Axiovision LE 4.8 software (Zeiss). Background fluorescence
intensity of each tissue section was also determined and
subtracted from the values obtained. Three L3-L5 sections (at
least 160 mm apart) from each animal were randomly selected
from at least 4 animals per experimental group.
2.11. Western blots
The lumbar spinal cord (L3-L5) and brain (cerebral cortex)
tissue from 6- to 7-month-old WT and TASTPM mice were
homogenized on ice in lysis buffer (Tris-HCl, 20 mM pH 7.5,
10 mM NaF, 150 mM NaCl, 1% Nonidet P-40, 1 mM phenyl-
methylsulfonyl fluoride fluoride, 1 mM Na3VO4, 10 mg/mL
leupeptin and trypsin inhibitor) with complete mini cocktail
protease inhibitor (Roche). Tissue lysates were then centri-
fuged at 13,000 rpm for 20 minutes at 4˚C. The protein
concentration of the supernatant was determined using the
NanoDrop spectrometer. Equal protein concentrations per
sample (60 mg protein) were added to Laemmli sample buffer,
boiled for 5 minutes, and subjected to 10% to 18% SDS-PAGE.
Wet transfer was performed using the Bio-Rad Trans-Blot Cell
(Bio-Rad Laboratories, Hertfordshire, United Kingdom) for 1
hour at 4˚C, and the membrane was then blocked with 5%
non–fat-dried milk in TBS-T (50 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 0.1% Tween 20) for 30minutes at room temperature. The
blot was probed with rabbit anti-VGLUT1 (1:1000; Cell
Signaling, Hertfordshire, United Kingdom), rabbit anti-
VGLUT2 (1:1000; Cell Signaling), and mouse anti-amyloid 1
to 16 (1:1000, 6E10; Cambridge Biosciences, United Kingdom)
antibodies. Results were visualised with horseradish
peroxidase–coupled anti-mouse or anti-rabbit immunoglobulin
(Dako) using enhanced chemiluminescence detection reagents
ECL (EMD Millipore, Hertfordshire, United Kingdom), Western
blotting detection system according to the manufacturer’s
Table 1
List of primary antibodies used for immunohistochemistry.
Antibody Species Dilution Source
6E10 Mouse 1:400/1:1000* Cambridge Biosciences
IBA1 Rabbit 1:1000 Wako (Hampshire, United Kingdom)
GFAP Rabbit 1:1000 Dako (Cambridge, United Kingdom)
CGRP Sheep 1:500 Enzo Life Sciences (Exeter, United
Kingdom)
NK1R Rabbit 1:10,000* Sigma-Aldrich
VGLUT1 Rabbit 1:5000 Synaptic Systems (Gottingen,
Germany)
VGLUT2 Guinea pig 1:250 Synaptic Systems
Met-ENK Rabbit 1:1000 Peninsula Laboratories (San Carlos,
CA)
NeuN Rabbit 1:1000 Cell Signaling
* Dilution for staining free-floating sections.
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instructions, and the immune complex visualized by the
BioSpectrum Imaging System. The protein bands were
densitometrically analyzed with Quantity One (Bio-Rad Labo-
ratories). Western blot for b-actin (1:1000; Cell Signaling) was
performed as control. Data were expressed as protein
expression relative to control.
2.12. Real-time PCR
Lumbar segments (L3-L5) of the spinal cord were dissected and
snap-frozen in liquid nitrogen and subsequently divided into
dorsal and ventral horn. Total RNA was then isolated from
minced dorsal horn tissue using the RNeasy mini-kit (Qiagen)
according to the manufacturer’s protocol. The total RNA
concentration was determined using the NanoDrop spectrom-
eter. Total RNA (50-100 ng) was used to synthesize first strand
cDNA, using Supersensitive III Reverse Transcriptase kit
(Thermo Fisher Science) according to the manufacturer’s
protocol. Expression levels of the following genes were
analysed: preproenkephalin (pPENK), proenkephalin (PENK),
and 18S rRNA were used reference transcripts. pPENK is the
precursor for PENK which contains peptides with 7 amino acid
sequences and produces enkephalin peptide.10 Amplification
was performed with a Light Cycler 480 (Roche) using Syber
Green I Master (Roche) using the primers: pPENK (TTCAGCA-
GATCGGAGGAGTTG and AGAAGCGAACGGAGGAGAGAT),9
PENK (ATGCAGCTACCGCCTGGTT and GTGTGCACGC-
CAGGAAATT),23 and 18S rRNA (GCTGGAATTACCGCGGCT
and CGGCTACCACATCCAAGGAA).9 The instrument was
programmed as follows: 95˚C for 5 minutes and 45 cycles of
3 steps of 10 seconds each including denaturing at 95˚C,
annealing at 60˚C, and primer extending at 72˚C. All samples
were run as duplicates and the 18S rRNA was used as the
housekeeping gene. The relative gene expression levels were
calculated according to the 2–DDCt method, where Ct repre-
sents the threshold cycle.
Figure 1.Cognitive and pathological features of the TASTPMmousemodel of Alzheimer’s disease (AD). TASTPM (9males and 6 females) mice displayedmemory
deficits compared with wild-type (WT) mice (5 males and 5 females) at the age of 6 and 7months but not earlier (A) (**P, 0.01, t test or Mann–Whitney Rank Sum
test). Data values are expressed as mean 6 SEM (n 5 10-15 per experimental group). Coronal brain sections from TASTPM mice (male) displayed AD-related
pathological hallmark namely amyloid plaques composed of aggregated Ab (B) accompanied by glial fibrillary acidic protein (GFAP)-positive astrocytes (C) and
ionized calcium binding adaptor molecule 1 (IBA1)-labelled microglia (D) forming a barrier around Ab pathology. The scale bar represents 1 mm (B) and 100 mm
(C–D). Ct, cerebral cortex; Hi, hippocampus; Th, thalamus.
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2.13. Statistical analysis
The data were analysed using SigmaPlot 12.5 (Systat
Software, San Jose, CA). The statistical tests performed and
the numbers of animals used are displayed in the Results
section and within the figure legends. Where data were not
normally distributed, the appropriate nonparametric test was
applied. All data are presented as mean 6 SEM and
a probability value less than 0.05 (P , 0.05) was considered
statistically significant.
3. Results
As expected, TASTPM mice displayed age-dependant memory
deficits in the novel object recognition test, as they spent significantly
less time exploring the novel object compared with WT mice at the
age of 6 and 7 months, but not at the age of 4 and 5 months (Fig.
1A). Obvious extracellular amyloid plaques, composed of aggre-
gated Ab, were observed in the brain of 6-month-old TASTPM
mice. These plaques were located specifically in the cortex and
hippocampus as well as in the thalamus (Fig. 1B). Amyloid plaques
in the brain were surrounded by barriers formed by astrocytes
(GFAP,Fig. 1C) andmicroglia (IBA1,Fig. 1D). Previous studies have
provided evidence for dystrophic neurites.15 In the spinal cord,
amyloid deposits were detected in 12-month-old TASTPM mice
and these deposits were accompanied by barriers formed by
astrocytes (GFAP, Fig. 2A–C) and microglia (IBA1, Fig. 2D–F).
However, no plaque pathology was observed in the spinal cord of
6-month-old TASTPM mice (Fig. 3).
In the spinal cords of 6-month-old TASTPM mice, but not WT
mice, we observed APP/Ab expression in the greymatter (Fig. 3A
and D). APP/Ab expression was mainly neuronal, as it was
observed in NeuN-positive cells in the TASTPM mice (Fig. 3D–F)
while absent in WT mice (Fig. 3A–C). APP/Ab was evidently
expressed in neurons in deep dorsal horn laminae (Fig. 3G–I) and
inmotor neurons in the ventral horn (Fig. 3J–L). In the dorsal horn,
APP/Ab was not coexpressed with the primary afferent marker
CGRP in laminae I and II (Fig. 4A–C). Similarly, APP/Ab did not
colocalise with NK1 receptor in neurons which are presumably
a subpopulation of projection neurons in lamina III (Fig. 4D–F). To
evaluate possible changes in excitatory function in TASTPMmice
spinal cord, we assessed the expression of vesicular glutamate
transporters VGLUT1 and VGLUT2. As previously reported,4 the
distribution of VGLUT1 profiles in WT spinal cords was mainly in
the deeper dorsal horn laminae (III-V) (Fig. 5A), and we observed
that this was not altered in the spinal cords of TASTPM mice
(Fig. 5B). As reported, VGLUT2 immunoreactivity was found
throughout the grey matter in WT spinal cords (Fig. 5C), but we
observed that VGLUT2 immunostainingwas less prominent in the
medial part of the deep dorsal horn in TASTPM spinal cords
(Fig. 5D). Quantitative analysis of VGLUT1 and VGLUT2
immunostaining intensity in the dorsal horn revealed significantly
reduced VGLUT2 staining intensity in the dorsal horn of the
TASTPMmice compared withWTmice, while no difference in the
expression of VGLUT1 was observed (Fig. 5G and H).
Furthermore, Western blot analysis of VGLUT1 and VGLUT2
proteins in the lumbar spinal cord showed significantly lower
Figure 2. Ab deposits in the spinal cord of 12-month-old TASTPM mice. Transverse lumbar spinal cord sections from 12-month-old TASTPM mice (male) were
stained with antibodies against b-amyloid 1-16 (6E10) (A and D) with either glial fibrillary acidic protein (GFAP) (B) or ionized calcium binding adaptor molecule 1
(IBA1) (E). Merged images are shown for 6E10 with GFAP (C) or IBA1 (F) co-immunostaining in the spinal cord. Pathological amyloid plaques composed of Ab are
evident in the dorsal (arrowheads) and ventral horns (arrows) of the spinal cord (A and D). A high-power magnification (insets) revealed GFAP (A–C) and IBA1 (D–F)
immunoreactivity surrounding the 6E10-labelled amyloid plaques in the dorsal and ventral horns. Scale bars: 200 mm (A–F) and 50 mm (insets).
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expression of VGLUT2, but not VGLUT1 in TASTPM mouse
tissue compared with WT mice controls (Fig. 5I and J).
Predictably, the expression of APP was present only in the
TASTPM spinal cords (Fig. 5K); however, Ab peptide was
undetectable in the spinal cord but observed in the cortex of the
transgenic TASTPM mice (Fig. 5L), where amyloid plaques were
detected (Fig. 1B). As in 6-month-old TASTPM mice the
presence of APP in the spinal cord is associated with a significant
decrease in expression of VGLUT2, these data suggest possible
alterations of the excitatory function. Many deep dorsal horn
neurons respond to noxious input and also send their dorsal
dendrites superficially into laminae I-III where they receive primary
afferent input from unmyelinated sensory fibres which respond to
noxious stimuli in the periphery.46 Thus, althoughwe observed no
significant APP/Ab expression in superficial laminae, we evalu-
ated whether TASTPM mice display sensory changes compared
with WT mice. TASTPM mice displayed increased response
latency to thermal stimulation compared with WT mice at the age
of 6 months, but not at the age of 4 months (Fig. 6A and B).
However, hind PWTs to mechanical stimulation in the TASTPM
micewere comparable withWTmice at the age of 4 and 6months
(Fig. 6CandD); andmotor coordinationwas no different fromWT
mice in any age group (Fig. 6E and F). In the carrageenan model
of inflammatory pain, we observed comparable development of
mechanical allodynia (Fig. 6G) and thermal hyperalgesia (Fig. 6H)
in the ipsilateral hind paw of 6- to 7-month-old TASTPM and WT
Figure 3. Ab expression in the spinal cord. Transverse lumbar spinal cord sections from 6- to 7-month-old TASTPM and wild-type (WT) male mice were stained
with antibodies against b-amyloid 1-16 (6E10) (A, D, G, and J) and neuronal nuclei marker (NeuN) (B, E, H, and K). Merged images are shown for 6E10 and NeuN
co-immunostaining in the spinal cord ofWT (C) and TASTPM (F) mice as well as TASTPMdorsal horn (I) and ventral horn (L). 6E10 staining was only detected in the
spinal cord of the transgenic TASTPMmice andwas distributed throughout the greymatter. A high-powermagnification revealed colocalisation of 6E10 andNeuN
in the dorsal horn laminae III-IV and motor neurons in the ventral horn of the transgenic TASTPM mice spinal cord. Scale bars: 500 mm (A–F) and 50 mm (G–L).
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mice at 3 hours after injection which was maintained at 24 hours.
Therefore, mice displaying amyloid plaques in the brain and
cognitive deficits, which are both indicative of development of
AD-like pathology in the brain, also display accumulation of APP/
Ab in spinal cord neurons and reduced sensitivity to acute
noxious heat stimuli applied to the hind paw in the periphery.
However, TASTPM mice responded normally to mechanical and
thermal noxious stimuli in a model of peripheral inflammatory
pain.
Notwithstanding the importance and relevance of the higher
structures in the brain in the perception and modulation of pain,
we focused this study on the dorsal horn of the spinal cord which
is the first relay station of noxious heat stimuli from the periphery.
In particular, we tested the hypothesis that an increased inhibitory
tone may underlie reduced thermal sensitivity in TASTPM mice.
Specifically, we examined the expression of the enkephalins, in
TASTPM mice which are reported to have high levels of opioid
peptides in the CSF similarly to patients with AD.29,33
We observed a significant increase of enkephalin immunoreac-
tivity in laminae I and II of the dorsal horn of 6-month-old TASTPM
mice compared with WT mice (Fig. 7A–C). Furthermore,
preproenkephalin (pPENK) and proenkephalin (PENK) mRNA
expression in TASTPM mice dorsal horn tissue extracts was
significantly higher than that in control tissue (Fig. 7D and E). The
preproenkephalins and proenkephalins are processed to generate
the enkephalin peptides.10 These data suggest an increased
opioidergic tone in TASTPMmice due to increased production and
release of enkephalins in the spinal cord. To test this possibility, we
administered the opioid receptor antagonist naloxone and
observed a significant reduction of TASTPM mice thermal thresh-
olds at 30minutes from injection compared with both baseline and
saline control values (Fig. 7F), whereasnaloxoneadministration did
not alter thresholds inWTmice. Altogether, thesedata suggest that
there is an age-dependant alteration in thermal sensitivity which
coincides with the onset of cognitive deficits. Intracellular APP/Ab
expression was detected only in the spinal cords of TASTPMmice
andwas accompanied by alterations in both the glutamatergic and
opioidergic systems in the spinal cord.
4. Discussion
In this study, we provide evidence for intraneuronal APP/Ab
accumulation in the spinal cords of TASTPMmice, in both dorsal
and ventral grey matters, thereby highlighting the presence of
early AD-like pathology in the spinal cord of 6-month-old
TASTPM mice. Further analysis revealed a decrease of gluta-
matergic interneuron marker VGLUT2 in the dorsal horn of
TASTPM mice compared with WT mice. Glutamate is present in
primary afferent terminals, projection neurons, and excitatory
interneurons in the spinal cord where it plays pronociceptive
roles.45 In nociceptive behavioural studies, the transgenic mice
exhibited an age-dependant decline in sensitivity to thermal
stimulation which could be attributed to a reduced glutamatergic
excitation and/or increased inhibition in the spinal cord. Indeed,
we found higher levels of pre–pro and proenkephalin mRNA and
enkephalin peptide expression in the dorsal horn of TASTPM
mice suggesting that an increased synthesis and release of
enkephalins in the spinal cord could result in elevated inhibitory
tone. This likely possibility is strengthened by our finding of the
reversal of thermal hyposensitivity following administration of the
opioid antagonist naloxone in TASTPM mice.
Cognitive deficits and amyloid plaques are among the major
clinical and pathological hallmarks of AD in the brain, respectively.
As expected, TASTPMmice display an age-dependant cognitive
impairment in the object recognition test which becomes
apparent at the age of 6months. In addition, extracellular amyloid
plaques accompanied by gliosis are present in the cerebral cortex
and hippocampus as well as the thalamus, a key relay station in
nociceptive signalling pathways.15 Collectively, these findings are
consistent with previous reports indicating that the TASTPM
mouse model recapitulates some of the key features of AD
clinically and pathologically.15,16
Figure 4.Ab absent in primary afferent terminals andNK1 receptor–positive neurons. Transverse spinal cord sections from6- to 7-month old TASTPMmice (male)
were stained with antibodies against b-amyloid 1-16 (6E10) (A and D), calcitonin gene-related peptide (CGRP) (B) and neurokinin 1 receptor (NK1R) (E). Merged
images are shown for 6E10 costained with CGRP (C) and NK1R (F). b-amyloid 1-16 was absent in primary afferent CGRP-immunopositive terminals and was also
not present in NK1R-positive neurons (arrows) in the dorsal horn lamina III of the TASTPM spinal cord. Scale bars: 100 mm (A–C) and 30 mm (D–F).
October 2016·Volume 157·Number 10 www.painjournalonline.com 2291
The novelty of this study is in providing evidence for intra-
neuronal accumulation of APP/Ab in both the dorsal (lamina III
and deeper) and ventral horns of the lumbar spinal cords of
TASTPM mice, while previous studies have primarily focused on
the brain. Previous studies have reported Ab pathology in the
5XFAD and Tg2576 transgenic mouse models of AD, but have
mainly focused on the dorsal column or the ventral horn and
suggested an association between intraneuronal Ab and motor
impairment.21,39,47 Differently, in this study despite the accumu-
lation of APP/Ab in ventral horns, no gross motor deficits were
detected in the TASTPM mice using the accelerating RotoRod
test. However, this may have been due to the fact that the
RotoRod may not have been a sensitive enough test to detect
subtle motor deficits.3 Furthermore, our study highlights the
presence of APP/Ab accumulation in both dorsal and ventral horn
neurons and assesses the impact on sensory and motor
behaviour in the transgenic TASTPM mice compared with WT
mice controls.
Intraneuronal Ab is associated with synaptic dysfunction
and early cognitive impairments before the development of the
AD pathological hallmark in the form of extracellular pla-
ques.30,19 The intracellular pool of Ab may act as a source for
the formation of extracellular plaques and the intracellular Ab
intensity decreases as the AD core pathology develops.27
Further evidence illustrates that intracellular Ab accumulates in
multivesicular bodies of neurons within the presynaptic and
postsynaptic compartments and a study in 3xTg model of AD
revealed synaptic dysfunction and long-term potentiating
(LTP) deficit before the presence of amyloid plaques.42,30
Therefore, we speculate that intraneuronal accumulation of
APP/Ab in the spinal cord of 6-month-old TASTPM mice is an
early-stage AD-like pathological feature which has the poten-
tial to induce synaptic dysfunction and contribute towards the
development of amyloid plaques, as observed in the spinal
cords of 12-month-old TASTPM mice, with progression of the
disease.
Figure 5.Ab and VGLUTs expression in the spinal cord. Transverse spinal cord sections from 6- to 7-month-old TASTPM and wild-type (WT) mice (male) were
stained with antibodies against vesicular glutamate transporter 1 (VGLUT1) (A and D) and vesicular glutamate transporter 2 (VGLUT2) (B and E). Merged
images are shown for VGLUT1 costaining with VGLUT2 (C and F). The distribution of VGLUT1 in TASTPM andWT spinal cord was mainly in the deeper dorsal
horn laminae (III-VI) (A and D), while VGLUT2 was found throughout the grey matter but with less prominence in the medial part of the TASTPM deep dorsal
horn (B and E). Quantitative analysis of VGLUT1 and VGLUT2 immunostaining intensity in the dorsal horn revealed significantly reduced VGLUT2 intensity in
the dorsal horn of the TASTPMmice compared withWT controls (*P, 0.05, t test, H) but no difference in VGLUT1 intensity (P. 0.05, t test, G). Data values are
expressed as mean 6 SEM (n 5 4 (2 males and 2 females) per experimental group). Scale bars: 200 mm (A–F). Quantitative levels of VGLUTs, amyloid
precursor protein (APP), and b-amyloid (Ab) determined by Western blot revealed significantly higher expression of APP and reduced levels of VGLUT2 in the
lumbar (L3-L5) spinal cord of TASTPMmice compared withWT controls (*P, 0.05, **P, 0.01, t test) relative to b-actin (loading control) (I–K). Ab peptide was
only detected in the TASTPM cerebral cortex, however, absent in both WT and TASTPM spinal cords (L). Data values are expressed as mean 6 SEM (n 5 3
[1 male and 2 females] per experimental group).
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APP/Abwere not found in primary afferent nociceptive terminals
in the superficial (laminae I-II) nor in the lamina I-III projection
neurons. Following activation by noxious stimuli in the periphery,
a subpopulation of primary afferent fibres release CGRP and
substance P (SP) alongside glutamate from their central terminals
in the dorsal horn and mediate nociceptive transmission through
activation of CGRP and NK1 receptors in projection neurons.
Ablation of NK1-R resulted in a significant attenuation of responses
to highly noxious stimuli (capsaicin) and mechanical hyperalge-
sia.24Whilst CGRP contributes in nociceptive transmission directly
and indirectly by potentiating the actions of SP through: promoting
release, inhibition of degradation, and regulating the expression of
Figure 6. Nociceptive thresholds and motor coordination. TASTPM mice (9 males and 7 females) displayed comparable nociceptive thresholds to wild-type (WT)
(5males and 5 females) mice in response to noxious thermal stimulation at the age of 4months (A); however, an increased pawwithdrawal latency comparedwithWT
mice at the age of 6 months (B) (*P , 0.05, Mann-Whitney Rank Sum test). TASTPM mice exhibited responses comparable with WT mice in response to noxious
mechanical stimulation (C and D). No motor deficit in the TASTPM mice at the age of 4 and 6 months, as no significant difference in the latency to fall from an
acceleratingRotoRodwasobservedwhencomparedwithWTcontrols (E and F). Data are expressed asmean6SEM (n5 10-16per experimental group).Mechanical
thresholds (G) and thermal withdrawal latencies (H) of the ipsilateral hind paw in response to intraplantar carrageenan (1%) injection in 6- to 7-month-old TASTPM and
WTmice. Both TASTPM andWTmice developed mechanical allodynia and thermal hyperalgesia 3 hours postcarrageenan, which persisted at 24 hours. At no point
were there any significant differences in behavioural responses of the TASTPM (2 males and 3 females) compared with WT controls (1 male and 3 females). Data are
presented as mean6 SEM (n5 4-5 per experimental group); 2-way repeated-measures analysis of variance followed by post hoc Tukey multiple comparison test
(#P , 0.05, ##P , 0.01, and ###P , 0.001 compared with respective baseline).
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NK1-R.26 Therefore, the lack of APP/Ab immunoreactivity in anNK1-
R–labelled subpopulation of presumed projection neurons implies
that APP/Abmay not directly affect the neurons relaying nociceptive
information to the supraspinal structures. Notably, recent evidence
suggests that theremay be a species difference between themouse
and rat, as many of the large lamina III anterolateral tract neurons in
the mouse do not show NK1 receptor immunoreactivity.5 We
therefore cannot rule out the possibility that lamina III anterolateral
Figure 7. Expression of enkephalins in the spinal cord and effect of naloxone on thermal thresholds. Transverse lumbar spinal cord sections from 6- to 7-month-old
TASTPM (5males and 5 females) andwild-type (WT) (4males and 4 females)micewere stainedwithmet-enkephalin (ENK) (A andB). Quantitative analysis ofmet-ENK
immunostaining in the dorsal horn revealed significantly highermet-ENK intensity in the dorsal horn of TASTPMcomparedwithWTcontrols (**P, 0.01,Mann-Whitney
Rank Sum test, C). Values are expressed as mean 6 SEM (n 5 8-10 per experimental group) and scale bar represents 200 mm. In addition, RT-PCR displayed
significantly highermRNAexpression of preproenkephalin (pPENK,D) and proenkephalin (PENK, E) in 6- to 7-month-old TASTPM (2males and 2 females) dorsal horn
(L3-L5) compared age-matched WT (4 females) controls (*P , 0.05, Mann-Whitney Rank Sum test). Data are expressed as mean6 SEM (n 5 4 per experimental
group). Administration of naloxone (1mg/kg intraperitoneally), an opioid antagonist, reduced pawwithdrawal latency in 6- to 7-month-old TASTPMmice (4males and
5 females) comparedwith baseline (###P, 0.001) andTASTPMsaline (4males and5 females) control (11P,0.01) after 30minutes. However, therewasnoeffect of
naloxone observed inWTmice (5males and5 females) comparedwith their respective baseline andWTsaline (5males and5 females) control. TASTPMmiceexhibited
significantly higher paw withdrawal latency compared with WT mice injected with saline at baseline and recovered back to baseline levels and significantly higher
3 hours after naloxone administration (*P, 0.05, **P, 0.01) using 2-way repeated-measures analysis of variance followed by Tukeymultiple comparison test (F). Data
are presented as mean6 SEM (n 5 9-10 per experimental group).
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tract neurons that lack the NK1 receptor may express APP/Ab.
However, APP/Ab immunoreactivity was present in deep dorsal horn
neuronswherewedetected a reduction in VGLUT2expression in the
lumbar segment of the spinal cord and especially in the dorsal horn
laminae IV-V. This finding may suggest that the presence of APP/Ab
is associated with glutamatergic dysfunction. Many lamina IV
neurons send their dorsal dendrites superficially into laminae I-III
and can receive primary afferent input from unmyelinated sensory
fibres which respond to noxious stimuli in the periphery.46 Thus, the
presenceofAPP/Ab in thedorsal hornof the spinal cordmay indicate
an alteration of glutamatergic function that, in turn, could reduce
nociceptive transmission and/or excitatory modulation.
In TASTPM mice, thresholds to noxious mechanical stimuli,
which evoke a spinal-mediated withdrawal reflex, were similar
to that of the WT mice controls. Similarly, after hind paw
inflammation, mechanical and thermal hypersensitivity de-
veloped with no difference between WT and TASTPM mice.
However, there was an age-dependant decrease in thresholds
to noxious stimulation in the hot-plate test, which also involves
supraspinal integration of nociceptive signals.13 Consistent
with these observations, reduced sensitivity to noxious thermal
stimuli has been observed to occur before any changes in
mechanical nociceptive thresholds in the CRND8 model of
AD41 and by us in the tail immersion test in TASTPM mice.8
Therefore, there may be a correlation between impaired
nociceptive responses and an increase in APP/Ab expression
in the spinal cord along with cognitive impairment. Intriguingly,
a longitudinal study found that patients with AD exhibit reduced
pain intensity and affect when compared with individuals
without dementia; thereby, supporting the possibility that the
pain experience is altered in AD35 and that the spinal expression
of APP/Ab may be a contributing factor.
To explore the underlying reason for the alteration of
TASTPM thermal nociceptive thresholds, the impact of opioid
levels on nociceptive behavioural responses was assessed.
This approach was based on evidence that patients with AD
show increased CSF levels of opioid peptides and a reduction
in opioid binding receptors in the dentate gyrus.20,29,33 In this
study, the opioid receptor antagonist, naloxone, induced an
increase in sensitivity to thermal stimulation suggesting that
increased opioidergic tone in the transgenic mice is re-
sponsible for the altered thermal thresholds. Furthermore,
histological and quantitative mRNA expression analysis
revealed increased expression of enkephalins in the dorsal
horn of the spinal cords of TASTPM mice compared with WT
mice. In a transgenic mouse model that overexpresses the
human APP (hAPP), increased levels of enkephalins have been
found in the hippocampus and entorhinal cortex which are
associated with neuronal and cognitive impairments.28 In
addition in an APP/PS transgenic mouse model of AD, evidence
reported in knockdown or antagonism of the delta opioid
receptor has revealed reductions in Ab accumulation, plaque
formation and associated gliosis, and behavioural deficits,
a result that supports the role of opioid peptides in Ab
generation.44
Altogether, these data in a transgenic mouse model of AD
show an age-dependant decline in sensitivity to acute noxious
thermal stimulation in a model that includes both spinal- and
supraspinal-mediated components. Thermal hyposensitivity
coincides with cognitive deficits and pathological amyloid
plaques in the brain as well as histopathological Ab plaques
and intraneuronal accumulation of APP/Ab in key regions
involved in nociceptive processing, namely the thalamus and
spinal cord, respectively.
The accumulation of intraneuronal APP/Ab in the spinal cord
was associated with an alteration of possible excitatory neuronal
markers, especially in the deeper laminae coupled with an
increased expression of endogenous opioid in superficial laminae
of the dorsal horn of the spinal cord. An increased inhibitory tone
mediated by endogenous opioid is likely to contribute significantly
to thermal hypoalgesia in AD transgenic mice.
Taken together, the findings of this study could have important
clinical implications for the care of patients with AD who have
deteriorating cognitive function along with reduced sensitivity to
pain, as altered thermal perception could be considered in
assessing clinical risk and may be associated with an increased
risk of injury during daily routine activities.
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